SEC 13F Intelligence

Managers / Q1 2022 · view latest →

Endurant Capital Management LP

CIK 0001633055 · 66 BOVET ROAD, SUITE 353, SAN MATEO, CA, 94402 · 650-539-5905

Reported Value
$380M
Q1 2022
Positions
63
Filings on Record
24
2019–present window
Filed
May 16, 2022
original filing

Summary

Endurant Capital Management LP reported $380M in U.S.-listed holdings across 63 positions for Q1 2022.

Its largest position, Invacare, represents 13.2% of the portfolio.

Compared with Q4 2021, the fund opened 23 new positions and exited 28.

Portfolio Metrics

Turnover
+33.2%
vs prior filed quarter
Top-10 Concentration
+45.5%
share of reported value
Largest Position
+13.2%
Invacare
New / Exited
23 / 28
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $189MQ4 ’18Q1 ’19: $253MQ2 ’19: $254MQ3 ’19: $279MQ3 ’19Q4 ’19: $317MQ1 ’20: $221MQ2 ’20: $1.8BQ2 ’20Q3 ’20: $338MQ4 ’20: $277MQ1 ’21: $384MQ1 ’21Q2 ’21: $364MQ3 ’21: $439MQ4 ’21: $414MQ4 ’21Q1 ’22: $380MQ2 ’22: $285MQ3 ’22: $307MQ3 ’22Q4 ’22: $246MQ1 ’23: $195MQ2 ’23: $115MQ2 ’23Q3 ’23: $111MQ4 ’23: $17MQ1 ’24: $0Q1 ’24filingsflow.com

Portfolio Composition

By security type
Common Stock: 56.3%ETP: 13.5%US DOMESTIC: 13.2%Other: 7.8%ADR: 6.6%Other: 2.5%
  • Common Stock · 56.3% · $214M
  • ETP · 13.5% · $51M
  • US DOMESTIC · 13.2% · $50M
  • Other · 7.8% · $30M
  • ADR · 6.6% · $25M
  • Other · 2.5% · $10M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
BMYBRISTOL-MYERS SQUIBB CONEW+194.7K194.7K+$14M$14M
MCKMCKESSON CORPNEW+29.2K29.2K+$9M$9M
EWEDWARDS LIFESCIENCES CORPNEW+44.6K44.6K+$5M$5M
ISRGINTUITIVE SURGICAL INCNEW+17.2K17.2K+$5M$5M
EHCENCOMPASS HEALTH CORPNEW+65.7K65.7K+$5M$5M
GALAPAGOS NVNEW+52.4K52.4K+$3M$3M
IDXXIDEXX LABS INCNEW+5.7K5.7K+$3M$3M
QIAGEN NVNEW+55.7K55.7K+$3M$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2022

48 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1INVACARE CORPNOTE 5.000%11/115.73%$60M66.82M
2CNCCENTENE CORP DELhistory →COM4.84%$18M218.2K
3LABORATORY CORP AMER HLDGSCOM NEW4.26%$16M61.3K
4AZNNASTRAZENECA PLChistory →SPONSORED ADR4.20%$16M240.3K
5BMYBRISTOL-MYERS SQUIBB COhistory →COM3.75%$14M194.7K
6OFIXORTHOFIX MED INChistory →COM3.75%$14M434.8K
7HUMHUMANA INChistory →COM3.34%$13M29.1K
8THCTENET HEALTHCARE CORPhistory →COM NEW2.97%$11M131.4K
98INSYNEOS HEALTH INChistory →CL A2.63%$10M123.2K
10AVTRAVANTOR INChistory →COM2.55%$10M285.9K
11BUWABIO RAD LABS INChistory →CL A2.54%$10M17.2K
12HO1HOLOGIC INChistory →COM2.50%$9M123.6K
13SIBNSI-BONE INChistory →COM2.46%$9M413.4K
14MCKMCKESSON CORPhistory →COM2.35%$9M29.2K
15CICIGNA CORP NEWhistory →COM1.81%$7M28.7K
16ELUTAZIYO BIOLOGICS INChistory →COM CL A1.74%$7M1.11M
17EWEDWARDS LIFESCIENCES CORPhistory →COM1.38%$5M44.6K
18ISRGINTUITIVE SURGICAL INChistory →COM NEW1.37%$5M17.2K
19EHCENCOMPASS HEALTH CORPhistory →COM1.23%$5M65.7K
20OCULOCULAR THERAPEUTIX INChistory →COM1.20%$5M924.0K
21ADAPYADAPTIMMUNE THERAPEUTICS PLChistory →SPONDS ADR1.17%$4M2.16M
22SELECTA BIOSCIENCES INCCOM1.12%$4M3.45M
23SPDR SER TRS&P BIOTECH1.10%$4M46.4K
24AXSMAXSOME THERAPEUTICS INChistory →COM1.09%$4M100.3K
25AHCOADAPTHEALTH CORPhistory →COMMON STOCK1.05%$4M248.3K
26IM8NINSMED INChistory →COM PAR $.011.02%$4M165.3K
27BDQMALBIREO PHARMA INCCOM0.95%$4M120.8K
28GALAPAGOS NVSPON ADR0.86%$3M52.4K
29IDXXIDEXX LABS INCCOM0.83%$3M5.7K
30QIAGEN NVSHS NEW0.72%$3M55.7K
312655957DPREMIER INCCL A0.71%$3M75.6K
32SUTRO BIOPHARMA INCCOM0.64%$2M296.5K
33MTDMETTLER TOLEDO INTERNATIONALCOM0.64%$2M1.8K
34FATEFATE THERAPEUTICS INCCOM0.61%$2M59.7K
35TNDMTANDEM DIABETES CARE INCCOM NEW0.56%$2M18.2K
36KARUNA THERAPEUTICS INCCOM0.51%$2M15.3K
37TXG10X GENOMICS INCCL A COM0.50%$2M24.9K
38BIOHAVEN PHARMACTL HLDG CO LCOM0.48%$2M15.4K
39VRTXVERTEX PHARMACEUTICALS INCCOM0.48%$2M7.0K
40ALNYALNYLAM PHARMACEUTICALS INCCOM0.45%$2M10.4K
41AFFIMED N VCOM0.41%$2M354.5K
42VRDNVIRIDIAN THERAPEUTICS INCCOM0.41%$2M83.2K
43GBTUSDGLOBAL BLOOD THERAPEUTICS INCOM0.39%$1M43.3K
44VTLUSDIMMUNIC INCCOM0.39%$1M130.6K
45ARGXARGENX SESPONSORED ADR0.37%$1M4.5K
46ICUIICU MED INCCOM0.36%$1M6.1K
47RCUSARCUS BIOSCIENCES INCCOM0.32%$1M38.6K
48RYTMRHYTHM PHARMACEUTICALS INCCOM0.32%$1M105.8K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2024$01May 7, 202413F-HRchanges · EDGAR ↗
Q4 2023$17M25Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$111M43Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$115M34Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$195M50May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$246M55Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$307M49Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$285M50Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$380M63May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$414M68Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$439M53Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$364M57Aug 27, 2021RESTATEMENTchanges · EDGAR ↗
Q1 2021$384M61May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$277M52Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$338M60Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.8B56Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$221M51May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$317M54Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$279M49Nov 25, 2019RESTATEMENTchanges · EDGAR ↗
Q2 2019$254M50Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$253M70May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$189M48Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.